Fragment-based molecular design of new competitive Dengue Den2 Ns2b/Ns3 inhibitors from the components of fingerroot (Boesenbergia rotunda)

In Silico Biology

Volumn 11, Issue 1-2, 2011, Pages 29-37

  Frimayanti, Neni ^a   Zain, Sharifuddin M ^a   Lee, Vannajan Sanghiran ^a,b   Wahab, Habibah A ^c   Yusof, Rohana ^a   Rahman, Noorsaadah Abd ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

Author keywords

Boesenbergia rotunda; Dengue DEN2 NS2B NS3; Docking; Fragment based

Indexed keywords

CHALCONE DERIVATIVE; LIGAND; NS3 PROTEASE, DENGUE VIRUS; PANDURATIN A; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; VIRUS PROTEIN;

ARTICLE; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; DENGUE; DENGUE VIRUS; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ENZYME ACTIVE SITE; GENETICS; HYDROGEN BOND; ZINGIBERACEAE;

CATALYTIC DOMAIN; CHALCONES; DENGUE; DENGUE VIRUS; DRUG DESIGN; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; MODELS, MOLECULAR; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS; ZINGIBERACEAE;

EID: 84859518076     PISSN: 14343207     EISSN: None     Source Type: Journal    
DOI: 10.3233/ISB-2012-0442     Document Type: Article

References (23)

1. K. Irie, P.M. Mohan, Y. Sasaguri and R. Putnak, Sequence analysis of cloned dengue virus type 2 genome (new guinea-c strain), Gene 1989 75, 197-211. (Pubitemid 19100121)
2. J.F. Bazan and R.J. Fletterick, Detection of a trypsin-like serine proetase domain in flaviviruses and pestiviruses. Virology 1989, 171, 637-639. (Pubitemid 19210412)
3. Chambers, T.J.; Nestorowicz, A.; Amberg, S.M.; Rice, C.M.,Mutagenesis of the yellow fever virus ns2b protein: Effects on proteolytic processing, ns2b-ns3 complex formation, and viral replication. J Virol 1993, 67, 6797-6807. (Pubitemid 23309150)
4. B. Falgout, M.P., Y. Zhang, C. lai, Both non structural proteins ns2b and ns3 are required for the proteolytic processing of dengue virus non structural protein. J Virol 1991, 65, 2467-2475.
5. A. Sampath, R.P., Molecular targets for flavivirus drug discovery. Antivir Res 2009, 81, 6-15.
6. Edelman, R., Dengue vaccines approach the finish line. Clin. Infect. Dis. Supple 2007, 1, 56-60.
7. McGee, C.; Lewis, M.; Claire, M.; Wagner, W.; Lang, J.; Guy, B.; Tsetsarkin, K.; Higgs, S.; Decelle, T., Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus asibi backbone sequences is dramatically attenuated in nonhuman primates J Infect Dis 2008, 197, 693-697. (Pubitemid 351364469)
8. Simasathien, S.; Thomas, S.; Watanaverradej, V.; Nisalak, A.; Barberousse, C.; Innis, B.; Sun, W.; Putnak, J.; Eckels, K.; Hutagalung, Y., et al., Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children J. Trop. Med. Hyg. 2008 78 426-433 (Pubitemid 351845193)
9. Laille, M.; Gerald, F.; Debitus, C., In vitro antiviral activity on dengue virus of marine natural products. Cell Mol. Life. Sci 1998, 54, 167-170. (Pubitemid 28134863)
10. Parida, M.; Upadhyay, C.; Pandya, G.; Jana, A., Inhibitory potential of neem (azadirachta indica juss) leaves on dengue virus type-2 replication Journal of Ethnopharmacology 2002, 79, 273-278. (Pubitemid 34136961)
11. Reis, S.; Valente, L.; Sampaio, A.; Siani, A.; Gandini, M.; Azeredo, E.; Avila, L.; Mazzei, J., Immunomodulating and antiviral activities of uncaria tomentosa on human monocytes infected with dengue virus-2. International Immunopharmacology 2008, 8, 468-476.
12. Tan, S.K.; Pippen, R.; Yusof, R.; Ibrahim, H.; Khalid; Rahman, N.A., Inhibitory activity of cylohexenyl chalcone derivatives and favanoids of fingerroot, boesenbergia rotunda (l), towards dengue-2 virus ns3 protease. Bioorg. Med. Chem. Lett 2006, 16, 3337-3340.
13. D'Arcy, A.; Chaillet, M.; Schiering, N.; Villard, F.; Lim, S.P.; Lefeuvre, P.; Erbel, P., Purification and crystallization of dengue and west nile virus ns2b-ns3 complexes. Acta. Crystallogr. Sect. F. Struct. Biol. Cryst. Commun 2006, 62, 157-162. (Pubitemid 44284023)
14. Erbel, P.; Schiering, N.; D'Arcy, A.; Renatus, M.; Kroemer, M.; Lim, S.P.; Yin, Z.; Keller, T.H.; Vasudevan, S.G.; Hommel, U., Structural basis for the activation of flaviviral ns3 proteases from dengue and west nile virus. Nat. Struct. Mol. Biol. 2006, 13, 372-373. (Pubitemid 43873510)
15. Campbell, S.J.; Gold, N.D.; Jackson, R.M.; Westhead, D.R., Ligand binding: Functional site location, similarity and docking. Current Opinion in Structural Biology 2003, 13, 389-395. (Pubitemid 36782467)
16. Kitchen, D.B.; Decornez, H.; Furr, J.R.; Baorath, J., Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Review. Drug Discovery 2004, 3, 935-949. (Pubitemid 39529931)
17. Mohan, V.; Gibbs, A.C.; Cummings, M.D.; Jaeger, E.P.; DesJarlais, R.L., Docking: Successes and challenges. Curr. Pharm. Des 2005, 11, 323-333. (Pubitemid 40277860)
18. Alexander, A.A.;Maria,M.F., Fragment-based drug discovery: What has it achieved so far? Current Topics in Medicinal Chemistry 2007, 7, 1554-1567.
19. Michele, N.S.; Roderick, E.H., Recent progress in fragment-based lead discovery. Current Opinion in Pharmacology 2009, 9, 1-7.
20. Kubinyi, H., 3d qsar in drug design: Theory, method and applications. Springer: 1993; Vol. 1.
21. Neni, F.; Chee, C.F.; Sharifuddin,M.; Noorsaadah, A.R., Design of newcompetitive dengue ns2b/ns3 protease inhibitors-a computational approach. Int. J. Mol. Sci 2011, 12, 1089-1100.
22. Brinkworth, R.I.; P, F.D.; R., Y.P., Homology model of the dengue virus ns3 protease: Putative interactions with both substrate and ns2b cofactor. J. Gen. Virol 1999, 80, 1167-1177.
23. Lee, Y.K.; Tan, S.; Habibah, A.; Rohana, Y.; Noorsaadah, A., Non substrate based inhibitors of dengue virus serine protease: A molecular docking approach to study binding interactions between protease and inhibitors. Aspac J. Mol. Biol. Biotechnol. 2007, 15, 53-59.